The effects of troglitazone, a novel thiazolidinedione, in non-insulin-dependent diabetic (NIDDM) patients were studied in a double-blind, parallel-group, placebo-controlled, dose-ranging trial. A total of 330 patients (63 % male), mean age 57 years (range 39-72), with two fasting capillary blood gl
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
โ Scribed by S. Kumar; A. J. M. Boulton; H. Beck-Nielsen; F. Berthezene; M. Muggeo; B. Persson; G. A. Spinas; S. Donoghue; S. Lettis; P. Stewart-Long; the Troglitazone study group
- Book ID
- 110609447
- Publisher
- Springer
- Year
- 1996
- Tongue
- English
- Weight
- 62 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0012-186X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The management of Type 2 diabetes mellitus with currently available oral agents may be complicated in the elderly by an increased frequency of side-effects. The effects of troglitazone, an insulin action enhancer, were studied in elderly patients with Type 2 diabetes in a double-blind, parallel-grou
Wtese"rn";lm-.r~.100mn,aS~n) ake (Body Mass Ind+n tBJ.ffk 33.8 f 5.4 k& fM f SEMJJ NJDDM re.tienbl w-en included in 001 studs. All HMlc vdus imp&d ri@antJy fmk S.4 i 19% 0 7.6 \* 18%. (P = O#J3J. After 6 momb8 aJJ p.lials rcrcJwJ 011 conb;ol ad mainlsnun of chaoSed ea& aid fiknjk cubits muld be achi